Switch theme
Sign up to access all valuation multiples
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
1995
291
LTM Revenue $87.6M
LTM EBITDA -$45.3M
$173M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pulmonx has a last 12-month revenue of $87.6M and a last 12-month EBITDA of -$45.3M.
In the most recent fiscal year, Pulmonx achieved revenue of $83.8M and an EBITDA of -$50.9M.
Pulmonx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pulmonx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $68.7M | $83.8M | XXX | XXX | XXX |
| Gross Profit | $39.9M | $50.8M | XXX | XXX | XXX |
| Gross Margin | 58% | 61% | XXX | XXX | XXX |
| EBITDA | -$55.5M | -$50.9M | XXX | XXX | XXX |
| EBITDA Margin | -81% | -61% | XXX | XXX | XXX |
| Net Profit | -$58.9M | -$60.8M | XXX | XXX | XXX |
| Net Margin | -86% | -73% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pulmonx's stock price is $5.
Pulmonx has current market cap of $218M, and EV of $173M.
See Pulmonx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $173M | $218M | XXX | XXX | XXX | XXX | $-1.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pulmonx has market cap of $218M and EV of $173M.
Pulmonx's trades at 2.0x LTM EV/Revenue multiple, and -3.8x LTM EBITDA.
Analysts estimate Pulmonx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pulmonx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $173M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | XXX | XXX |
| P/E | -3.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPulmonx's NTM/LTM revenue growth is 17%
Pulmonx's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Pulmonx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pulmonx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pulmonx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -61% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -44% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 143% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pulmonx acquired XXX companies to date.
Last acquisition by Pulmonx was XXXXXXXX, XXXXX XXXXX XXXXXX . Pulmonx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pulmonx founded? | Pulmonx was founded in 1995. |
| Where is Pulmonx headquartered? | Pulmonx is headquartered in United States of America. |
| How many employees does Pulmonx have? | As of today, Pulmonx has 291 employees. |
| Who is the CEO of Pulmonx? | Pulmonx's CEO is Mr. Steven S. Williamson. |
| Is Pulmonx publicy listed? | Yes, Pulmonx is a public company listed on NAS. |
| What is the stock symbol of Pulmonx? | Pulmonx trades under LUNG ticker. |
| When did Pulmonx go public? | Pulmonx went public in 2020. |
| Who are competitors of Pulmonx? | Similar companies to Pulmonx include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Pulmonx? | Pulmonx's current market cap is $218M |
| What is the current revenue of Pulmonx? | Pulmonx's last 12-month revenue is $87.6M. |
| What is the current EBITDA of Pulmonx? | Pulmonx's last 12-month EBITDA is -$45.3M. |
| What is the current EV/Revenue multiple of Pulmonx? | Current revenue multiple of Pulmonx is 2.0x. |
| What is the current EV/EBITDA multiple of Pulmonx? | Current EBITDA multiple of Pulmonx is -3.8x. |
| What is the current revenue growth of Pulmonx? | Pulmonx revenue growth between 2023 and 2024 was 22%. |
| Is Pulmonx profitable? | Yes, Pulmonx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
